Rituximab in steroid refractory autoimmune hemolytic anemia

The exact role of vascular imaging with respect to monitoring of disease activity and prediction of disease relapse has not clearly been defined in giant cell arteritis. For this reason, patients with giant cell arteritis who are enrolled in the GiACTA trial can participate in a positron emission tomography-computed tomography (PET/CT) substudy. Selected patients will undergo a PET/CT of the neck, chest, abdomen and pelvis after one year of treatment to scan the large arteries for radiographic evidence of vascular inflammation. The goal of this substudy is to determine the proportion of patients with radiographic activity and the correlation of radiographic findings with the risk of subsequent disease relapse.

Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:   12 Years to 75 Years   (Child, Adult, Senior) Sexes Eligible for Study:   All Accepts Healthy Volunteers:   No Criteria

  1. Adults aged 18-75 years old and children aged 12-17 years old.
  2. Active lupus nephritis, as defined by kidney biopsy within prior 8 weeks assessed by the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification:

    Rituximab in steroid refractory autoimmune hemolytic anemia

    rituximab in steroid refractory autoimmune hemolytic anemia

    Media:

    rituximab in steroid refractory autoimmune hemolytic anemiarituximab in steroid refractory autoimmune hemolytic anemiarituximab in steroid refractory autoimmune hemolytic anemiarituximab in steroid refractory autoimmune hemolytic anemiarituximab in steroid refractory autoimmune hemolytic anemia

http://buy-steroids.org